United States Food and Drug Administration (USFDA) has completed inspection at Solara Active Pharma Science’s multi-product manufacturing facility at Cuddalore with ZERO 483s inspectional observations.
The USFDA inspection at the facility was scheduled and completed between July 1, 2019 and July 5, 2019. The company continues to stay focused on maintaining the highest level of compliance across its manufacturing facilities. This is company’s third consecutive US FDA audit with Zero 483s.
Solara Active Pharma Sciences is a young, dynamic, entrepreneurial and customer oriented API manufacturer.
